What is Abivax?
Abivax, established in 2013 and headquartered in Paris, France, is dedicated to mobilizing the body's innate immune defenses. The company's research and development efforts are focused on addressing critical unmet medical needs in autoimmune diseases, viral infections, and cancer. By leveraging its expertise in immunology, Abivax aims to deliver innovative treatments that offer significant clinical benefits to patients worldwide. Its pipeline targets diseases with substantial patient populations and limited therapeutic options.
How much funding has Abivax raised?
Abivax has raised a total of $67M across 3 funding rounds:
Debt
$436K
Debt
$17.6M
Other Financing Round
$49M
Debt (2017): $436K with participation from Region Occitanie and Bpifrance
Debt (2020): $17.6M led by Kreos Capital
Other Financing Round (2022): $49M supported by Venrock Healthcare Capital Partners and Tcgx
Key Investors in Abivax
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners is an investment firm likely specializing in providing capital to healthcare and biotechnology companies, supporting their growth and development.
Tcgx
Information regarding Tcgx's specific investment focus is not readily available, but its participation suggests an interest in the biotechnology sector.
Kreos Capital
Kreos Capital is a prominent provider of growth capital and debt financing solutions, typically backing technology and life sciences companies during their expansion phases.
What's next for Abivax?
The recent major strategic investment signals a pivotal growth phase for Abivax. This capital infusion is expected to fuel the advancement of its clinical pipeline, potentially enabling the company to reach key development milestones and expand its research capabilities. The strategic nature of the financing suggests strong confidence from investors in Abivax's scientific platform and its potential to disrupt current treatment paradigms in oncology and immunology. Future endeavors will likely focus on progressing its lead candidates through late-stage clinical trials and preparing for potential commercialization.
See full Abivax company page
